Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

A phase I, open‐label study (NCT02197234) assessed the effects of osimertinib on simvastatin exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer and disease progression post‐EGFR tyrosine kinase inhibitor treatment. Here, we report on a retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Vishwanathan, Karthick, Cantarini, Mireille, So, Karen, Masson, Eric, Fetterolf, Jennifer, Ramalingam, Suresh S., Harvey, R. Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951454/
https://www.ncbi.nlm.nih.gov/pubmed/31498564
http://dx.doi.org/10.1111/cts.12688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951454/
https://www.ncbi.nlm.nih.gov/pubmed/31498564
http://dx.doi.org/10.1111/cts.12688

Ejemplares similares